The IGFBP-3 ELISA is for the quantitative determination of bioactive IGFBP-3 in human serum and plasma. For Research Use only. Not For In Vitro Diagnostic Use.
Research Use Only. Not for Use in Diagnostic Procedures.
Product Distribution
Available Worldwide
Range
0.4 - 30 ng/mL
Sensitivity
0.18 ng/ml
Sizes
96 Wells
Sample Types
Heparin Plasma, Serum
Inc Time Hour
3
Inc Time Minute
30
Inc Time Overnight
No
Inc Time See Protocol
No
Sample Size
10
Detection
Colorimetric
All currently existing IGFBP-3 immunoassays use the binding of specific anti-IGFBP-3 antibodies for signal generation and thus IGFBP-3 quantification. The failure of differentiation between complete IGFBP-3 molecules and their respective fragments (derived physiologically due to the different proteases activities) is unavoidable in this system. Because one molecule IGFBP-3 can be cleaved in several fragments often false high quantitative values are measured. Based on this methodology it is not possible to differentiate between high IGFBP-3 levels in fact, or, a high degree of fragmentation. The incidental attempts to use monoclonal antibodies with a binding region represented only by the intact IGFBP-3 molecule are indirect, imprecise and insufficient. The activities of all effective proteases, which have different sites of action and therefore generate different kind of fragments, are disregarded. IGFBP-3, however, enables to determine the real functional and effective bioactive IGFBP-3, functional in terms of binding ability of the mainly interesting natural ligand, namely IGF-I.
1. What percentage of your IgE allergy testing panel consists of molecular allergens rather than allergen extracts? The ALEX2 IgE allergen panel consists of 117 extracts and 183 molecular allergens. This represents the largest panel of molecular allergens on the market, including 50 unique...
Cases of food and environmental allergies have been increasing over the last decade. While conservative estimates suggest IgE-mediated allergy affects 6-8% of children and 2-3% of adults, some estimates are as high as 30%.3, 2 Symptoms can range from mild to severe and include itching, hives,...
Food sensitivity or food intolerance involves a non-allergic response to a food or food additive. In a recent on-line survey conducted in the U.S., 24% of adults aged 18 to 79 reported a food intolerance. While a food allergy is typically mediated by IgE antibodies, adverse reactions to food...
The ALPCO Glucagon ELISA is for the quantitative determination of glucagon in human EDTA plasma. This assay was developed for ease-of-use and demonstrates superior sensitivity while eliminating cross-reactivity issues present in other commercially-available assays.
ALPCO’s automated turbidimetric solution for calprotectin testing offers enhanced efficiency without compromising clinical sensitivity or specificity. Clinicians can prioritize endoscopic evaluation for the patients that need it most and quickly put IBS patients on the right treatment path.
Join our speaker from Department of Pathology , University of Utah School of Medicine, Dr. Heather Nelson, to discuss how to validate and launch a FDA-approved assay.
Energy homeostasis is a focus of research into diabetes and obesity. Read about how our assays in this area can assist both academic and industry researchers.
Complement System Solutions for Drug Development and Clinical Research Datasheet
The complement system is essential to innate immunity from a variety of diseases. ALPCO’s full range of complement system immunoassays can drive discovery.
Melatonin Products for Sleep Disorder-Related Research Datasheet
The melatonin hormone affects the circadian rhythm and sleep-wake cycle. Find out about our immunoassays and products that explore melatonin and sleep disorders.
